ACE阻害剤の世界市場レポート 2025年

ACE阻害剤の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.4％で96億米ドルに成長します。予測期間の成長は、心血管疾患の世界的な負担の増加、高血圧治療ガイドラインの拡大、併用療法の進歩、心不全管理への注力、認知度の向上、医療アクセスに起因すると考えられます。予測期間における主な動向としては、腎臓保護への注力、レニン・アンジオテンシン系阻害薬への嗜好、ジェネリック医薬品との競合と価格圧力、ヘルスケアにおける患者中心のアプローチ、規制の更新、安全性への配慮などが挙げられます。

高血圧症の有病率の高まりは、ACE阻害剤市場の成長を牽引する極めて重要な役割を果たすと予想されます。高血圧は血管内の圧力上昇を特徴とします。ACE阻害剤は、アンジオテンシン変換酵素阻害剤のカテゴリーに属し、高血圧の治療と管理に使用される一群の薬剤を表しています。これらの薬剤は血管を弛緩させ、血圧の低下と血流量の増加をもたらします。2023年3月現在、世界保健機関（WHO）の報告によると、高血圧に罹患している30～79歳の成人は世界で推定12億8,000万人であり、その3分の2は低・中所得国に居住しています。過去30年間で、30～79歳の高血圧患者は6億5,000万人と大幅に増加しています。驚くべきことに、成人の高血圧患者の約46％が、診断不足のために自分の状態に気づいていません。この高血圧症例の急増は、ACE阻害剤市場の成長を推進する重要な要因となっています。

心臓疾患の罹患率の上昇は、今後数年間のACE阻害剤市場の成長を促進すると予想されます。心臓疾患には、冠動脈疾患、心不全、不整脈など、心臓や血管に影響を及ぼすさまざまな病状が含まれます。ACE阻害剤は、血管収縮、ナトリウム貯留、アルドステロン分泌を抑制し、最終的に心臓機能を改善するアンジオテンシン変換酵素を阻害することにより、これらの病態を管理するのに不可欠です。例えば、2024年9月、英国を拠点とする心臓血管研究の慈善団体である英国心臓財団（British Heart Foundation）は、英国では約760万人が心臓および循環器疾患とともに生活しており、その内訳は男性約400万人、女性約360万人であると報告しました。これらの疾患は英国における全死亡の約27％を占め、年間17万人以上、1日あたり約480人、つまり3分に1人が死亡していることになります。このように、心臓疾患の有病率の増加がACE阻害剤市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のACE阻害剤市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のACE阻害剤市場：成長率分析
• 世界のACE阻害剤市場の実績：規模と成長、2019～2024年
• 世界のACE阻害剤市場の予測：規模と成長、2024～2029年、2034年
• 世界のACE阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のACE阻害剤市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• スルフィドリル含有剤
• ジカルボキシレート含有剤
• ホスホネート含有剤
• 世界のACE阻害剤市場：薬物別、実績と予測、2019～2024年、2024～2029年、2034年
• ラミプリル
• エナラプリル
• ベナゼプリル
• フォシノプリル
• カプトプリル
• モエキシプリル
• その他
• 世界のACE阻害剤市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口錠剤
• 経口溶液
• 世界のACE阻害剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 心不全
• 慢性腎臓病
• 高血圧
• 糖尿病
• 心臓発作
• その他
• 世界のACE阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• オンラインドラッグストア
• その他
• 世界のACE阻害剤市場：スルフィドリル含有剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• カプトプリル
• ゾフェノプリル
• 世界のACE阻害剤市場：ジカルボキシレート含有剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エナラプリル
• リシノプリル
• ラミプリル
• キナプリル
• ベナゼプリル
• ペリンドプリル
• 世界のACE阻害剤市場：ホスホネート含有剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• フォシノプリル

第7章 地域別・国別分析

• 世界のACE阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のACE阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ACE阻害剤市場：競合情勢
• ACE阻害剤市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Co.
• Takeda Pharmaceuticals Company
• Daiichi Sankyo Company Ltd.
• UCB Schwarz Pharma Inc.
• Endo International plc
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories
• Abbott Laboratories
• Eli Lilly and Company
• Cipla Limited
• GlaxoSmithKline plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ACE阻害剤市場2029年：新たな機会を提供する国
• ACE阻害剤市場2029年：新たな機会を提供するセグメント
• ACE阻害剤市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

ACE inhibitors, or angiotensin-converting enzyme inhibitors, constitute a class of medications utilized for the treatment and management of hypertension. Their mechanism of action involves the inhibition of the body's production of angiotensin II, a chemical responsible for constricting blood vessels and raising blood pressure. The primary purpose of ACE inhibitors is to induce relaxation in veins and arteries, ultimately leading to a reduction in blood pressure.

The main categories of ACE inhibitors encompass sulfhydryl-containing agents, dicarboxylate-containing agents, and phosphonate-containing agents. Sulfhydryl-containing agents are compounds characterized by the presence of a sulfhydryl group (-SH) in their structure. Various drugs fall into this category, including ramipril, enalapril, benazepril, fosinopril, captopril, moexipril, and others. These medications are available in diverse dosage forms, such as oral tablets and oral solutions. They find application in the treatment of various conditions, including heart failure, chronic kidney disease, hypertension, diabetes, and heart attacks. These medications are utilized by a range of end-users, including hospitals and online drug stores.

The countries covered in the ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The ACE inhibitors market size has grown steadily in recent years. It will grow from$7.15 billion in 2024 to $7.48 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to risen cardiovascular disease incidence, increased aging population, clinical effectiveness and safety profile, prevalence of diabetes, regulatory endorsement and guidelines

The ACE inhibitors market size is expected to see strong growth in the next few years. It will grow to $9.6 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing global burden of cardiovascular diseases, expanding hypertension treatment guidelines, advancements in combination therapies, focus on heart failure management, rising awareness and healthcare access. Major trends in the forecast period include focus on kidney protection, preference for renin-angiotensin system inhibitors, generic competition and pricing pressures, patient-centric approaches in healthcare, regulatory updates and safety considerations.

The escalating prevalence of hypertension disorders is anticipated to play a pivotal role in driving the growth of the ACE inhibitors market. Hypertension, or high blood pressure, is characterized by elevated pressure within the blood vessels. ACE inhibitors, belonging to the category of angiotensin-converting enzyme inhibitors, represent a group of medications employed for the treatment and management of hypertension. These medications operate by relaxing blood vessels, leading to a reduction in blood pressure and an enhancement in blood flow. As of March 2023, the World Health Organization reported that an estimated 1.28 billion adults aged 30 to 79 worldwide were affected by hypertension, with two-thirds of these individuals residing in low- and middle-income nations. Over the past three decades, there has been a substantial increase of 650 million people aged 30 to 79 with hypertension. Alarmingly, around 46% of adults with hypertension are unaware of their condition due to a lack of diagnosis. This surge in hypertension cases stands as a significant factor propelling the growth of the ACE inhibitors market.

The rising incidence of cardiac disorders is expected to drive the growth of the ACE inhibitors market in the coming years. Cardiac disorders encompass a variety of medical conditions affecting the heart and blood vessels, including coronary artery disease, heart failure, and arrhythmias. ACE inhibitors are vital in managing these conditions by blocking the angiotensin-converting enzyme, which helps reduce vasoconstriction, sodium retention, and aldosterone secretion, ultimately improving heart function. For example, in September 2024, the British Heart Foundation, a UK-based cardiovascular research charity, reported that approximately 7.6 million people in the UK are living with heart and circulatory diseases, including around 4 million men and 3.6 million women. These conditions account for about 27% of all deaths in the UK, resulting in over 170,000 deaths annually, or roughly 480 deaths per day-equivalent to one death every three minutes. As a result, the growing prevalence of cardiac disorders is fueling the expansion of the ACE inhibitors market.

A notable trend with a strong emphasis on product innovations, as major companies strategically develop novel products to strengthen their market positions and gain a competitive advantage. For instance, in February 2023, Travere Therapeutics, a US-based biopharmaceutical company, achieved FDA approval for FILSPARI (sparsentan). This groundbreaking non-immunosuppressive therapy is intended for use in patients with IgA nephropathy (IgAN). FILSPARI represents a significant advancement as the only approved non-immunosuppressive therapy. It is an oral medication designed for once-daily use by adults with primary IgAN who are at risk of rapid disease progression, typically presenting with a UPCR of less than 1.5 g/g and proteinuria. This approval marks a noteworthy milestone in treatment options for IgAN, supplementing traditional approaches involving systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive medications, including angiotensin-receptor blockers (ARBs).

Leading companies in the ACE inhibitor market are increasingly focusing on launching generic drugs to strengthen their competitive position. Generic drugs contain the same active ingredients, dosage, safety, strength, and effectiveness as brand-name medications but are typically sold at a lower cost once the original drug's patent expires. For example, in August 2023, Pharmascience Inc., a Canada-based pharmaceutical company, introduced pms-PERINDOPRIL-INDAPAMIDE, a generic medication designed for the initial treatment of mild to moderate essential hypertension (high blood pressure) in adults. This combination drug contains perindopril erbumine, an ACE inhibitor that helps relax blood vessels, and indapamide, a diuretic that aids in eliminating excess fluid and sodium from the body. These ingredients work together to effectively reduce blood pressure across a wide patient population. pms-PERINDOPRIL-INDAPAMIDE is available in several dosage combinations, including 2 mg, 4 mg, and 8 mg of perindopril erbumine with 0.625 mg, 1.25 mg, and 2.5 mg of indapamide, respectively.

In January 2023, AstraZeneca, a UK-based pharmaceutical company, made a significant acquisition by purchasing CinCor Pharma for $1.3 billion. This strategic move positions AstraZeneca to expand its product line of aldosterone synthase inhibitors (ASI), particularly for blood pressure lowering in the treatment of resistant hypertension. CinCor Pharma, a US-based clinical-stage biopharmaceutical company, specializes in developing novel treatments for resistant and uncontrolled hypertension, as well as chronic kidney disease. This acquisition aligns with AstraZeneca's overarching goal of diversifying its portfolio and addressing critical medical needs in the cardiovascular therapeutic area.

Major companies operating in the ACE inhibitors market include Pfizer Inc., Novartis AG, Johnson & Johnson Private Limited, Merck KGaA, Sanofi S.A., Bayer AG, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Co., Takeda Pharmaceuticals Company, Daiichi Sankyo Company Ltd., UCB Schwarz Pharma Inc., Endo International plc, Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim, Bausch Health Companies Inc., Dr. Reddy's Laboratories, Abbott Laboratories, Eli Lilly and Company, Cipla Limited, GlaxoSmithKline plc, Cadila Healthcare Limited, AbbVie Inc., Sandoz Group AG, Accord Healthcare Ltd., AstraZeneca plc, Lupin Limited, Macleods Pharmaceuticals Limited, Zydus lifescience Ltd., Apotex Inc.

North America was the largest region in the ACE inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the ace inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The global ACE inhibitors market consists of sales of various drugs including zofenopril, perindopril, enalapril, trandolapril. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

ACE Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on ace inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ace inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The ace inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Sulfhydryl-containing Agents; Dicarboxylate-containing Agents; Phosphonate-containing Agents
• 2) By Drug: Ramipril; Enalapril; Benazepril; Fosinopril; Captopril; Moexipril; Other Drugs
• 3) By Dosage Form: Oral Tablets; Oral Solutions
• 4) By Application: Heart Failure; Chronic Kidney Disease; Hypertension; Diabetes; Heart Attack; Other Applications
• 5) By End-Users: Hospitals; Online Drug Stores; Other End-Users
• Subsegments:
• 1) By Sulfhydryl-Containing Agents: Captopril; Zofenopril
• 2) By Dicarboxylate-Containing Agents: Enalapril; Lisinopril; Ramipril; Quinapril; Benazepril; Perindopril
• 3) By Phosphonate-Containing Agents: Fosinopril
• Companies Mentioned: Pfizer Inc.; Novartis AG; Johnson & Johnson Private Limited; Merck KGaA; Sanofi S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. ACE Inhibitors Market Characteristics

3. ACE Inhibitors Market Trends And Strategies

4. ACE Inhibitors Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global ACE Inhibitors Growth Analysis And Strategic Analysis Framework

• 5.1. Global ACE Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global ACE Inhibitors Market Growth Rate Analysis
• 5.4. Global ACE Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global ACE Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global ACE Inhibitors Total Addressable Market (TAM)

6. ACE Inhibitors Market Segmentation

• 6.1. Global ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sulfhydryl-containing Agents
• Dicarboxylate-containing Agents
• Phosphonate-containing Agents
• 6.2. Global ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ramipril
• Enalapril
• Benazepril
• Fosinopril
• Captopril
• Moexipril
• Other Drugs
• 6.3. Global ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Oral Solutions
• 6.4. Global ACE Inhibitors Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Heart Failure
• Chronic Kidney Disease
• Hypertension
• Diabetes
• Heart Attack
• Other Applications
• 6.5. Global ACE Inhibitors Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Online Drug Stores
• Other End-Users
• 6.6. Global ACE Inhibitors Market, Sub-Segmentation Of Sulfhydryl-Containing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Captopril
• Zofenopril
• 6.7. Global ACE Inhibitors Market, Sub-Segmentation Of Dicarboxylate-Containing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enalapril
• Lisinopril
• Ramipril
• Quinapril
• Benazepril
• Perindopril
• 6.8. Global ACE Inhibitors Market, Sub-Segmentation Of Phosphonate-Containing Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fosinopril

7. ACE Inhibitors Market Regional And Country Analysis

• 7.1. Global ACE Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global ACE Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific ACE Inhibitors Market

• 8.1. Asia-Pacific ACE Inhibitors Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China ACE Inhibitors Market

• 9.1. China ACE Inhibitors Market Overview
• 9.2. China ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India ACE Inhibitors Market

• 10.1. India ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan ACE Inhibitors Market

• 11.1. Japan ACE Inhibitors Market Overview
• 11.2. Japan ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia ACE Inhibitors Market

• 12.1. Australia ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia ACE Inhibitors Market

• 13.1. Indonesia ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea ACE Inhibitors Market

• 14.1. South Korea ACE Inhibitors Market Overview
• 14.2. South Korea ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe ACE Inhibitors Market

• 15.1. Western Europe ACE Inhibitors Market Overview
• 15.2. Western Europe ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK ACE Inhibitors Market

• 16.1. UK ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany ACE Inhibitors Market

• 17.1. Germany ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France ACE Inhibitors Market

• 18.1. France ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy ACE Inhibitors Market

• 19.1. Italy ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain ACE Inhibitors Market

• 20.1. Spain ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe ACE Inhibitors Market

• 21.1. Eastern Europe ACE Inhibitors Market Overview
• 21.2. Eastern Europe ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia ACE Inhibitors Market

• 22.1. Russia ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America ACE Inhibitors Market

• 23.1. North America ACE Inhibitors Market Overview
• 23.2. North America ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA ACE Inhibitors Market

• 24.1. USA ACE Inhibitors Market Overview
• 24.2. USA ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada ACE Inhibitors Market

• 25.1. Canada ACE Inhibitors Market Overview
• 25.2. Canada ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America ACE Inhibitors Market

• 26.1. South America ACE Inhibitors Market Overview
• 26.2. South America ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil ACE Inhibitors Market

• 27.1. Brazil ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East ACE Inhibitors Market

• 28.1. Middle East ACE Inhibitors Market Overview
• 28.2. Middle East ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa ACE Inhibitors Market

• 29.1. Africa ACE Inhibitors Market Overview
• 29.2. Africa ACE Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa ACE Inhibitors Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa ACE Inhibitors Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. ACE Inhibitors Market Competitive Landscape And Company Profiles

• 30.1. ACE Inhibitors Market Competitive Landscape
• 30.2. ACE Inhibitors Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Private Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis

31. ACE Inhibitors Market Other Major And Innovative Companies

• 31.1. Bayer AG
• 31.2. Teva Pharmaceutical Industries Ltd.
• 31.3. Bristol-Myers Squibb Co.
• 31.4. Takeda Pharmaceuticals Company
• 31.5. Daiichi Sankyo Company Ltd.
• 31.6. UCB Schwarz Pharma Inc.
• 31.7. Endo International plc
• 31.8. Sun Pharmaceutical Industries Ltd.
• 31.9. Boehringer Ingelheim
• 31.10. Bausch Health Companies Inc.
• 31.11. Dr. Reddy's Laboratories
• 31.12. Abbott Laboratories
• 31.13. Eli Lilly and Company
• 31.14. Cipla Limited
• 31.15. GlaxoSmithKline plc

32. Global ACE Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The ACE Inhibitors Market

34. Recent Developments In The ACE Inhibitors Market

35. ACE Inhibitors Market High Potential Countries, Segments and Strategies

• 35.1 ACE Inhibitors Market In 2029 - Countries Offering Most New Opportunities
• 35.2 ACE Inhibitors Market In 2029 - Segments Offering Most New Opportunities
• 35.3 ACE Inhibitors Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer